nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—CYP2E1—liver cancer	0.395	1	CbGaD
Citalopram—HTR2C—Sorafenib—liver cancer	0.0817	0.247	CbGbCtD
Citalopram—CYP2B6—Sorafenib—liver cancer	0.0507	0.153	CbGbCtD
Citalopram—CYP2C19—Sorafenib—liver cancer	0.0322	0.0973	CbGbCtD
Citalopram—CYP2B6—Doxorubicin—liver cancer	0.0308	0.0929	CbGbCtD
Citalopram—CYP1A2—Sorafenib—liver cancer	0.0297	0.0897	CbGbCtD
Citalopram—ABCB1—Sorafenib—liver cancer	0.026	0.0785	CbGbCtD
Citalopram—CYP2D6—Sorafenib—liver cancer	0.0245	0.0739	CbGbCtD
Citalopram—ABCB1—Doxorubicin—liver cancer	0.0158	0.0476	CbGbCtD
Citalopram—CYP3A4—Sorafenib—liver cancer	0.0156	0.047	CbGbCtD
Citalopram—CYP2D6—Doxorubicin—liver cancer	0.0149	0.0449	CbGbCtD
Citalopram—CYP3A4—Doxorubicin—liver cancer	0.00945	0.0285	CbGbCtD
Citalopram—Orthostatic hypotension—Doxorubicin—liver cancer	0.000151	0.000791	CcSEcCtD
Citalopram—Abdominal pain upper—Doxorubicin—liver cancer	0.000151	0.000791	CcSEcCtD
Citalopram—Hypokalaemia—Doxorubicin—liver cancer	0.000151	0.000788	CcSEcCtD
Citalopram—Angina pectoris—Epirubicin—liver cancer	0.000151	0.000788	CcSEcCtD
Citalopram—Rash—Sorafenib—liver cancer	0.00015	0.000785	CcSEcCtD
Citalopram—Dermatitis—Sorafenib—liver cancer	0.00015	0.000784	CcSEcCtD
Citalopram—Breast disorder—Doxorubicin—liver cancer	0.00015	0.000783	CcSEcCtD
Citalopram—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000149	0.00078	CcSEcCtD
Citalopram—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000149	0.00078	CcSEcCtD
Citalopram—Headache—Sorafenib—liver cancer	0.000149	0.00078	CcSEcCtD
Citalopram—Bronchitis—Epirubicin—liver cancer	0.000149	0.000778	CcSEcCtD
Citalopram—Nasopharyngitis—Doxorubicin—liver cancer	0.000148	0.000775	CcSEcCtD
Citalopram—Pancytopenia—Epirubicin—liver cancer	0.000147	0.000769	CcSEcCtD
Citalopram—Gastritis—Doxorubicin—liver cancer	0.000147	0.000767	CcSEcCtD
Citalopram—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000146	0.000764	CcSEcCtD
Citalopram—Muscular weakness—Doxorubicin—liver cancer	0.000146	0.000764	CcSEcCtD
Citalopram—Dysuria—Epirubicin—liver cancer	0.000145	0.000757	CcSEcCtD
Citalopram—Abdominal distension—Doxorubicin—liver cancer	0.000144	0.000754	CcSEcCtD
Citalopram—Upper respiratory tract infection—Epirubicin—liver cancer	0.000144	0.000752	CcSEcCtD
Citalopram—Asthma—Doxorubicin—liver cancer	0.000143	0.000749	CcSEcCtD
Citalopram—Influenza—Doxorubicin—liver cancer	0.000143	0.000749	CcSEcCtD
Citalopram—Dysphagia—Doxorubicin—liver cancer	0.000143	0.000749	CcSEcCtD
Citalopram—Pollakiuria—Epirubicin—liver cancer	0.000143	0.000748	CcSEcCtD
Citalopram—Eosinophilia—Doxorubicin—liver cancer	0.000142	0.000741	CcSEcCtD
Citalopram—Nausea—Sorafenib—liver cancer	0.000141	0.00074	CcSEcCtD
Citalopram—Photosensitivity reaction—Epirubicin—liver cancer	0.000141	0.000739	CcSEcCtD
Citalopram—Weight increased—Epirubicin—liver cancer	0.000141	0.000736	CcSEcCtD
Citalopram—Pancreatitis—Doxorubicin—liver cancer	0.00014	0.000734	CcSEcCtD
Citalopram—Weight decreased—Epirubicin—liver cancer	0.00014	0.000732	CcSEcCtD
Citalopram—Hyperglycaemia—Epirubicin—liver cancer	0.00014	0.00073	CcSEcCtD
Citalopram—Angina pectoris—Doxorubicin—liver cancer	0.000139	0.000729	CcSEcCtD
Citalopram—Pneumonia—Epirubicin—liver cancer	0.000139	0.000726	CcSEcCtD
Citalopram—Infestation—Epirubicin—liver cancer	0.000138	0.000722	CcSEcCtD
Citalopram—Infestation NOS—Epirubicin—liver cancer	0.000138	0.000722	CcSEcCtD
Citalopram—Bronchitis—Doxorubicin—liver cancer	0.000138	0.00072	CcSEcCtD
Citalopram—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000137	0.000715	CcSEcCtD
Citalopram—Pancytopenia—Doxorubicin—liver cancer	0.000136	0.000711	CcSEcCtD
Citalopram—Neuropathy peripheral—Epirubicin—liver cancer	0.000135	0.000707	CcSEcCtD
Citalopram—Stomatitis—Epirubicin—liver cancer	0.000134	0.000703	CcSEcCtD
Citalopram—Jaundice—Epirubicin—liver cancer	0.000134	0.000703	CcSEcCtD
Citalopram—Urinary tract infection—Epirubicin—liver cancer	0.000134	0.000701	CcSEcCtD
Citalopram—Conjunctivitis—Epirubicin—liver cancer	0.000134	0.000701	CcSEcCtD
Citalopram—Dysuria—Doxorubicin—liver cancer	0.000134	0.0007	CcSEcCtD
Citalopram—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000133	0.000696	CcSEcCtD
Citalopram—Sweating—Epirubicin—liver cancer	0.000132	0.000692	CcSEcCtD
Citalopram—Pollakiuria—Doxorubicin—liver cancer	0.000132	0.000692	CcSEcCtD
Citalopram—Haematuria—Epirubicin—liver cancer	0.000131	0.000688	CcSEcCtD
Citalopram—Photosensitivity reaction—Doxorubicin—liver cancer	0.000131	0.000683	CcSEcCtD
Citalopram—Hepatobiliary disease—Epirubicin—liver cancer	0.00013	0.000682	CcSEcCtD
Citalopram—Weight increased—Doxorubicin—liver cancer	0.00013	0.000681	CcSEcCtD
Citalopram—Epistaxis—Epirubicin—liver cancer	0.00013	0.000681	CcSEcCtD
Citalopram—Weight decreased—Doxorubicin—liver cancer	0.000129	0.000677	CcSEcCtD
Citalopram—Sinusitis—Epirubicin—liver cancer	0.000129	0.000677	CcSEcCtD
Citalopram—Hyperglycaemia—Doxorubicin—liver cancer	0.000129	0.000675	CcSEcCtD
Citalopram—Agranulocytosis—Epirubicin—liver cancer	0.000129	0.000673	CcSEcCtD
Citalopram—Pneumonia—Doxorubicin—liver cancer	0.000128	0.000672	CcSEcCtD
Citalopram—Infestation NOS—Doxorubicin—liver cancer	0.000128	0.000668	CcSEcCtD
Citalopram—Infestation—Doxorubicin—liver cancer	0.000128	0.000668	CcSEcCtD
Citalopram—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000126	0.000662	CcSEcCtD
Citalopram—Bradycardia—Epirubicin—liver cancer	0.000126	0.000659	CcSEcCtD
Citalopram—Neuropathy peripheral—Doxorubicin—liver cancer	0.000125	0.000654	CcSEcCtD
Citalopram—Haemoglobin—Epirubicin—liver cancer	0.000124	0.000651	CcSEcCtD
Citalopram—Jaundice—Doxorubicin—liver cancer	0.000124	0.000651	CcSEcCtD
Citalopram—Stomatitis—Doxorubicin—liver cancer	0.000124	0.000651	CcSEcCtD
Citalopram—Rhinitis—Epirubicin—liver cancer	0.000124	0.000649	CcSEcCtD
Citalopram—Conjunctivitis—Doxorubicin—liver cancer	0.000124	0.000649	CcSEcCtD
Citalopram—Urinary tract infection—Doxorubicin—liver cancer	0.000124	0.000649	CcSEcCtD
Citalopram—Haemorrhage—Epirubicin—liver cancer	0.000124	0.000648	CcSEcCtD
Citalopram—Hepatitis—Epirubicin—liver cancer	0.000124	0.000648	CcSEcCtD
Citalopram—Hypoaesthesia—Epirubicin—liver cancer	0.000123	0.000644	CcSEcCtD
Citalopram—Pharyngitis—Epirubicin—liver cancer	0.000123	0.000643	CcSEcCtD
Citalopram—Sweating—Doxorubicin—liver cancer	0.000122	0.00064	CcSEcCtD
Citalopram—Urinary tract disorder—Epirubicin—liver cancer	0.000122	0.00064	CcSEcCtD
Citalopram—Oedema peripheral—Epirubicin—liver cancer	0.000122	0.000638	CcSEcCtD
Citalopram—Haematuria—Doxorubicin—liver cancer	0.000122	0.000637	CcSEcCtD
Citalopram—Connective tissue disorder—Epirubicin—liver cancer	0.000122	0.000637	CcSEcCtD
Citalopram—Urethral disorder—Epirubicin—liver cancer	0.000121	0.000635	CcSEcCtD
Citalopram—Hepatobiliary disease—Doxorubicin—liver cancer	0.000121	0.000631	CcSEcCtD
Citalopram—Epistaxis—Doxorubicin—liver cancer	0.00012	0.00063	CcSEcCtD
Citalopram—Sinusitis—Doxorubicin—liver cancer	0.00012	0.000626	CcSEcCtD
Citalopram—Visual impairment—Epirubicin—liver cancer	0.000119	0.000624	CcSEcCtD
Citalopram—Agranulocytosis—Doxorubicin—liver cancer	0.000119	0.000623	CcSEcCtD
Citalopram—Erythema multiforme—Epirubicin—liver cancer	0.000117	0.000612	CcSEcCtD
Citalopram—Bradycardia—Doxorubicin—liver cancer	0.000117	0.00061	CcSEcCtD
Citalopram—Eye disorder—Epirubicin—liver cancer	0.000116	0.000605	CcSEcCtD
Citalopram—Tinnitus—Epirubicin—liver cancer	0.000115	0.000604	CcSEcCtD
Citalopram—Haemoglobin—Doxorubicin—liver cancer	0.000115	0.000602	CcSEcCtD
Citalopram—Flushing—Epirubicin—liver cancer	0.000115	0.000601	CcSEcCtD
Citalopram—Cardiac disorder—Epirubicin—liver cancer	0.000115	0.000601	CcSEcCtD
Citalopram—Rhinitis—Doxorubicin—liver cancer	0.000115	0.000601	CcSEcCtD
Citalopram—Hepatitis—Doxorubicin—liver cancer	0.000115	0.000599	CcSEcCtD
Citalopram—Haemorrhage—Doxorubicin—liver cancer	0.000115	0.000599	CcSEcCtD
Citalopram—Hypoaesthesia—Doxorubicin—liver cancer	0.000114	0.000596	CcSEcCtD
Citalopram—Pharyngitis—Doxorubicin—liver cancer	0.000114	0.000595	CcSEcCtD
Citalopram—Urinary tract disorder—Doxorubicin—liver cancer	0.000113	0.000592	CcSEcCtD
Citalopram—Oedema peripheral—Doxorubicin—liver cancer	0.000113	0.00059	CcSEcCtD
Citalopram—Connective tissue disorder—Doxorubicin—liver cancer	0.000113	0.000589	CcSEcCtD
Citalopram—Angiopathy—Epirubicin—liver cancer	0.000112	0.000588	CcSEcCtD
Citalopram—Urethral disorder—Doxorubicin—liver cancer	0.000112	0.000588	CcSEcCtD
Citalopram—Immune system disorder—Epirubicin—liver cancer	0.000112	0.000585	CcSEcCtD
Citalopram—Mediastinal disorder—Epirubicin—liver cancer	0.000112	0.000584	CcSEcCtD
Citalopram—Chills—Epirubicin—liver cancer	0.000111	0.000581	CcSEcCtD
Citalopram—Arrhythmia—Epirubicin—liver cancer	0.000111	0.000579	CcSEcCtD
Citalopram—Visual impairment—Doxorubicin—liver cancer	0.00011	0.000578	CcSEcCtD
Citalopram—Alopecia—Epirubicin—liver cancer	0.000109	0.000572	CcSEcCtD
Citalopram—Mental disorder—Epirubicin—liver cancer	0.000108	0.000567	CcSEcCtD
Citalopram—Erythema multiforme—Doxorubicin—liver cancer	0.000108	0.000567	CcSEcCtD
Citalopram—Malnutrition—Epirubicin—liver cancer	0.000108	0.000564	CcSEcCtD
Citalopram—Erythema—Epirubicin—liver cancer	0.000108	0.000564	CcSEcCtD
Citalopram—Eye disorder—Doxorubicin—liver cancer	0.000107	0.00056	CcSEcCtD
Citalopram—Tinnitus—Doxorubicin—liver cancer	0.000107	0.000559	CcSEcCtD
Citalopram—Flushing—Doxorubicin—liver cancer	0.000106	0.000556	CcSEcCtD
Citalopram—Cardiac disorder—Doxorubicin—liver cancer	0.000106	0.000556	CcSEcCtD
Citalopram—Flatulence—Epirubicin—liver cancer	0.000106	0.000556	CcSEcCtD
Citalopram—Tension—Epirubicin—liver cancer	0.000106	0.000553	CcSEcCtD
Citalopram—Dysgeusia—Epirubicin—liver cancer	0.000106	0.000552	CcSEcCtD
Citalopram—Nervousness—Epirubicin—liver cancer	0.000105	0.000548	CcSEcCtD
Citalopram—Back pain—Epirubicin—liver cancer	0.000104	0.000545	CcSEcCtD
Citalopram—Angiopathy—Doxorubicin—liver cancer	0.000104	0.000544	CcSEcCtD
Citalopram—Muscle spasms—Epirubicin—liver cancer	0.000104	0.000542	CcSEcCtD
Citalopram—Immune system disorder—Doxorubicin—liver cancer	0.000103	0.000541	CcSEcCtD
Citalopram—Mediastinal disorder—Doxorubicin—liver cancer	0.000103	0.00054	CcSEcCtD
Citalopram—Chills—Doxorubicin—liver cancer	0.000103	0.000538	CcSEcCtD
Citalopram—Arrhythmia—Doxorubicin—liver cancer	0.000102	0.000535	CcSEcCtD
Citalopram—Vision blurred—Epirubicin—liver cancer	0.000102	0.000531	CcSEcCtD
Citalopram—Alopecia—Doxorubicin—liver cancer	0.000101	0.00053	CcSEcCtD
Citalopram—Mental disorder—Doxorubicin—liver cancer	0.0001	0.000525	CcSEcCtD
Citalopram—Ill-defined disorder—Epirubicin—liver cancer	0.0001	0.000523	CcSEcCtD
Citalopram—Erythema—Doxorubicin—liver cancer	9.97e-05	0.000522	CcSEcCtD
Citalopram—Malnutrition—Doxorubicin—liver cancer	9.97e-05	0.000522	CcSEcCtD
Citalopram—Anaemia—Epirubicin—liver cancer	9.96e-05	0.000521	CcSEcCtD
Citalopram—Agitation—Epirubicin—liver cancer	9.9e-05	0.000518	CcSEcCtD
Citalopram—Flatulence—Doxorubicin—liver cancer	9.82e-05	0.000514	CcSEcCtD
Citalopram—Tension—Doxorubicin—liver cancer	9.78e-05	0.000512	CcSEcCtD
Citalopram—Dysgeusia—Doxorubicin—liver cancer	9.76e-05	0.000511	CcSEcCtD
Citalopram—Malaise—Epirubicin—liver cancer	9.72e-05	0.000508	CcSEcCtD
Citalopram—Nervousness—Doxorubicin—liver cancer	9.68e-05	0.000507	CcSEcCtD
Citalopram—Vertigo—Epirubicin—liver cancer	9.68e-05	0.000507	CcSEcCtD
Citalopram—Syncope—Epirubicin—liver cancer	9.66e-05	0.000506	CcSEcCtD
Citalopram—Leukopenia—Epirubicin—liver cancer	9.65e-05	0.000505	CcSEcCtD
Citalopram—Back pain—Doxorubicin—liver cancer	9.64e-05	0.000505	CcSEcCtD
Citalopram—Muscle spasms—Doxorubicin—liver cancer	9.59e-05	0.000502	CcSEcCtD
Citalopram—Palpitations—Epirubicin—liver cancer	9.52e-05	0.000498	CcSEcCtD
Citalopram—Loss of consciousness—Epirubicin—liver cancer	9.47e-05	0.000496	CcSEcCtD
Citalopram—Cough—Epirubicin—liver cancer	9.4e-05	0.000492	CcSEcCtD
Citalopram—Vision blurred—Doxorubicin—liver cancer	9.4e-05	0.000492	CcSEcCtD
Citalopram—Convulsion—Epirubicin—liver cancer	9.34e-05	0.000489	CcSEcCtD
Citalopram—Hypertension—Epirubicin—liver cancer	9.3e-05	0.000487	CcSEcCtD
Citalopram—Ill-defined disorder—Doxorubicin—liver cancer	9.25e-05	0.000484	CcSEcCtD
Citalopram—Anaemia—Doxorubicin—liver cancer	9.22e-05	0.000482	CcSEcCtD
Citalopram—Arthralgia—Epirubicin—liver cancer	9.17e-05	0.00048	CcSEcCtD
Citalopram—Chest pain—Epirubicin—liver cancer	9.17e-05	0.00048	CcSEcCtD
Citalopram—Myalgia—Epirubicin—liver cancer	9.17e-05	0.00048	CcSEcCtD
Citalopram—Agitation—Doxorubicin—liver cancer	9.16e-05	0.000479	CcSEcCtD
Citalopram—Anxiety—Epirubicin—liver cancer	9.14e-05	0.000478	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	9.11e-05	0.000477	CcSEcCtD
Citalopram—Discomfort—Epirubicin—liver cancer	9.06e-05	0.000474	CcSEcCtD
Citalopram—Malaise—Doxorubicin—liver cancer	8.99e-05	0.00047	CcSEcCtD
Citalopram—Dry mouth—Epirubicin—liver cancer	8.97e-05	0.000469	CcSEcCtD
Citalopram—Vertigo—Doxorubicin—liver cancer	8.96e-05	0.000469	CcSEcCtD
Citalopram—Syncope—Doxorubicin—liver cancer	8.94e-05	0.000468	CcSEcCtD
Citalopram—Leukopenia—Doxorubicin—liver cancer	8.92e-05	0.000467	CcSEcCtD
Citalopram—Confusional state—Epirubicin—liver cancer	8.87e-05	0.000464	CcSEcCtD
Citalopram—Palpitations—Doxorubicin—liver cancer	8.81e-05	0.000461	CcSEcCtD
Citalopram—Anaphylactic shock—Epirubicin—liver cancer	8.79e-05	0.00046	CcSEcCtD
Citalopram—Oedema—Epirubicin—liver cancer	8.79e-05	0.00046	CcSEcCtD
Citalopram—Loss of consciousness—Doxorubicin—liver cancer	8.76e-05	0.000459	CcSEcCtD
Citalopram—Infection—Epirubicin—liver cancer	8.74e-05	0.000457	CcSEcCtD
Citalopram—Cough—Doxorubicin—liver cancer	8.7e-05	0.000455	CcSEcCtD
Citalopram—Shock—Epirubicin—liver cancer	8.65e-05	0.000453	CcSEcCtD
Citalopram—Convulsion—Doxorubicin—liver cancer	8.64e-05	0.000452	CcSEcCtD
Citalopram—Nervous system disorder—Epirubicin—liver cancer	8.62e-05	0.000451	CcSEcCtD
Citalopram—Thrombocytopenia—Epirubicin—liver cancer	8.61e-05	0.000451	CcSEcCtD
Citalopram—Hypertension—Doxorubicin—liver cancer	8.61e-05	0.00045	CcSEcCtD
Citalopram—Tachycardia—Epirubicin—liver cancer	8.58e-05	0.000449	CcSEcCtD
Citalopram—Skin disorder—Epirubicin—liver cancer	8.54e-05	0.000447	CcSEcCtD
Citalopram—Hyperhidrosis—Epirubicin—liver cancer	8.5e-05	0.000445	CcSEcCtD
Citalopram—Chest pain—Doxorubicin—liver cancer	8.49e-05	0.000444	CcSEcCtD
Citalopram—Myalgia—Doxorubicin—liver cancer	8.49e-05	0.000444	CcSEcCtD
Citalopram—Arthralgia—Doxorubicin—liver cancer	8.49e-05	0.000444	CcSEcCtD
Citalopram—Anxiety—Doxorubicin—liver cancer	8.46e-05	0.000443	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	8.43e-05	0.000441	CcSEcCtD
Citalopram—Discomfort—Doxorubicin—liver cancer	8.39e-05	0.000439	CcSEcCtD
Citalopram—Anorexia—Epirubicin—liver cancer	8.38e-05	0.000439	CcSEcCtD
Citalopram—Dry mouth—Doxorubicin—liver cancer	8.3e-05	0.000434	CcSEcCtD
Citalopram—Hypotension—Epirubicin—liver cancer	8.22e-05	0.00043	CcSEcCtD
Citalopram—Confusional state—Doxorubicin—liver cancer	8.2e-05	0.000429	CcSEcCtD
Citalopram—Anaphylactic shock—Doxorubicin—liver cancer	8.14e-05	0.000426	CcSEcCtD
Citalopram—Oedema—Doxorubicin—liver cancer	8.14e-05	0.000426	CcSEcCtD
Citalopram—Infection—Doxorubicin—liver cancer	8.08e-05	0.000423	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Epirubicin—liver cancer	8.01e-05	0.000419	CcSEcCtD
Citalopram—Shock—Doxorubicin—liver cancer	8.01e-05	0.000419	CcSEcCtD
Citalopram—Nervous system disorder—Doxorubicin—liver cancer	7.98e-05	0.000418	CcSEcCtD
Citalopram—Thrombocytopenia—Doxorubicin—liver cancer	7.97e-05	0.000417	CcSEcCtD
Citalopram—Insomnia—Epirubicin—liver cancer	7.95e-05	0.000416	CcSEcCtD
Citalopram—Tachycardia—Doxorubicin—liver cancer	7.94e-05	0.000416	CcSEcCtD
Citalopram—Skin disorder—Doxorubicin—liver cancer	7.9e-05	0.000414	CcSEcCtD
Citalopram—Paraesthesia—Epirubicin—liver cancer	7.9e-05	0.000413	CcSEcCtD
Citalopram—Hyperhidrosis—Doxorubicin—liver cancer	7.87e-05	0.000412	CcSEcCtD
Citalopram—Dyspnoea—Epirubicin—liver cancer	7.84e-05	0.00041	CcSEcCtD
Citalopram—Somnolence—Epirubicin—liver cancer	7.82e-05	0.000409	CcSEcCtD
Citalopram—Anorexia—Doxorubicin—liver cancer	7.76e-05	0.000406	CcSEcCtD
Citalopram—Dyspepsia—Epirubicin—liver cancer	7.74e-05	0.000405	CcSEcCtD
Citalopram—Decreased appetite—Epirubicin—liver cancer	7.64e-05	0.0004	CcSEcCtD
Citalopram—Hypotension—Doxorubicin—liver cancer	7.6e-05	0.000398	CcSEcCtD
Citalopram—Gastrointestinal disorder—Epirubicin—liver cancer	7.59e-05	0.000397	CcSEcCtD
Citalopram—Fatigue—Epirubicin—liver cancer	7.58e-05	0.000397	CcSEcCtD
Citalopram—Constipation—Epirubicin—liver cancer	7.52e-05	0.000394	CcSEcCtD
Citalopram—Pain—Epirubicin—liver cancer	7.52e-05	0.000394	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Doxorubicin—liver cancer	7.41e-05	0.000388	CcSEcCtD
Citalopram—Insomnia—Doxorubicin—liver cancer	7.36e-05	0.000385	CcSEcCtD
Citalopram—Paraesthesia—Doxorubicin—liver cancer	7.31e-05	0.000382	CcSEcCtD
Citalopram—Dyspnoea—Doxorubicin—liver cancer	7.25e-05	0.00038	CcSEcCtD
Citalopram—Feeling abnormal—Epirubicin—liver cancer	7.25e-05	0.000379	CcSEcCtD
Citalopram—Somnolence—Doxorubicin—liver cancer	7.23e-05	0.000379	CcSEcCtD
Citalopram—Gastrointestinal pain—Epirubicin—liver cancer	7.19e-05	0.000376	CcSEcCtD
Citalopram—Dyspepsia—Doxorubicin—liver cancer	7.16e-05	0.000375	CcSEcCtD
Citalopram—Decreased appetite—Doxorubicin—liver cancer	7.07e-05	0.00037	CcSEcCtD
Citalopram—Gastrointestinal disorder—Doxorubicin—liver cancer	7.03e-05	0.000368	CcSEcCtD
Citalopram—Fatigue—Doxorubicin—liver cancer	7.02e-05	0.000367	CcSEcCtD
Citalopram—Urticaria—Epirubicin—liver cancer	6.99e-05	0.000366	CcSEcCtD
Citalopram—Constipation—Doxorubicin—liver cancer	6.96e-05	0.000364	CcSEcCtD
Citalopram—Pain—Doxorubicin—liver cancer	6.96e-05	0.000364	CcSEcCtD
Citalopram—Abdominal pain—Epirubicin—liver cancer	6.95e-05	0.000364	CcSEcCtD
Citalopram—Body temperature increased—Epirubicin—liver cancer	6.95e-05	0.000364	CcSEcCtD
Citalopram—Feeling abnormal—Doxorubicin—liver cancer	6.71e-05	0.000351	CcSEcCtD
Citalopram—Gastrointestinal pain—Doxorubicin—liver cancer	6.65e-05	0.000348	CcSEcCtD
Citalopram—Hypersensitivity—Epirubicin—liver cancer	6.48e-05	0.000339	CcSEcCtD
Citalopram—Urticaria—Doxorubicin—liver cancer	6.46e-05	0.000338	CcSEcCtD
Citalopram—Body temperature increased—Doxorubicin—liver cancer	6.43e-05	0.000337	CcSEcCtD
Citalopram—Abdominal pain—Doxorubicin—liver cancer	6.43e-05	0.000337	CcSEcCtD
Citalopram—Asthenia—Epirubicin—liver cancer	6.31e-05	0.00033	CcSEcCtD
Citalopram—Pruritus—Epirubicin—liver cancer	6.22e-05	0.000326	CcSEcCtD
Citalopram—Diarrhoea—Epirubicin—liver cancer	6.02e-05	0.000315	CcSEcCtD
Citalopram—Hypersensitivity—Doxorubicin—liver cancer	6e-05	0.000314	CcSEcCtD
Citalopram—Asthenia—Doxorubicin—liver cancer	5.84e-05	0.000306	CcSEcCtD
Citalopram—Dizziness—Epirubicin—liver cancer	5.82e-05	0.000304	CcSEcCtD
Citalopram—Pruritus—Doxorubicin—liver cancer	5.76e-05	0.000301	CcSEcCtD
Citalopram—Vomiting—Epirubicin—liver cancer	5.59e-05	0.000293	CcSEcCtD
Citalopram—Diarrhoea—Doxorubicin—liver cancer	5.57e-05	0.000291	CcSEcCtD
Citalopram—Rash—Epirubicin—liver cancer	5.55e-05	0.00029	CcSEcCtD
Citalopram—Dermatitis—Epirubicin—liver cancer	5.54e-05	0.00029	CcSEcCtD
Citalopram—Headache—Epirubicin—liver cancer	5.51e-05	0.000288	CcSEcCtD
Citalopram—Dizziness—Doxorubicin—liver cancer	5.38e-05	0.000282	CcSEcCtD
Citalopram—Nausea—Epirubicin—liver cancer	5.22e-05	0.000273	CcSEcCtD
Citalopram—Vomiting—Doxorubicin—liver cancer	5.17e-05	0.000271	CcSEcCtD
Citalopram—Rash—Doxorubicin—liver cancer	5.13e-05	0.000268	CcSEcCtD
Citalopram—Dermatitis—Doxorubicin—liver cancer	5.13e-05	0.000268	CcSEcCtD
Citalopram—Headache—Doxorubicin—liver cancer	5.1e-05	0.000267	CcSEcCtD
Citalopram—Nausea—Doxorubicin—liver cancer	4.83e-05	0.000253	CcSEcCtD
Citalopram—CYP1A2—Metabolism—PSMD10—liver cancer	8.14e-06	9.8e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PPARA—liver cancer	8.14e-06	9.79e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—IL2—liver cancer	8.14e-06	9.79e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TERT—liver cancer	8.11e-06	9.75e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GGT1—liver cancer	8.07e-06	9.71e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GOT1—liver cancer	8.07e-06	9.71e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CRABP1—liver cancer	8.06e-06	9.7e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CG—liver cancer	8.03e-06	9.67e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—APC—liver cancer	8.03e-06	9.67e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GOT2—liver cancer	7.92e-06	9.53e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GSTP1—liver cancer	7.88e-06	9.48e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—HMOX1—liver cancer	7.77e-06	9.35e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GSTP1—liver cancer	7.69e-06	9.25e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—HMOX1—liver cancer	7.59e-06	9.13e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KDR—liver cancer	7.56e-06	9.09e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—BRAF—liver cancer	7.55e-06	9.09e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KDR—liver cancer	7.53e-06	9.06e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAPK14—liver cancer	7.51e-06	9.03e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAPK14—liver cancer	7.48e-06	9e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CYP2E1—liver cancer	7.45e-06	8.96e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KDR—liver cancer	7.41e-06	8.92e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAPK14—liver cancer	7.37e-06	8.86e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ESR1—liver cancer	7.36e-06	8.86e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ESR1—liver cancer	7.34e-06	8.83e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—F2—liver cancer	7.27e-06	8.75e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—F2—liver cancer	7.25e-06	8.72e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GSTP1—liver cancer	7.25e-06	8.72e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GSTM1—liver cancer	7.24e-06	8.71e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ESR1—liver cancer	7.23e-06	8.69e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	7.21e-06	8.67e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—HMOX1—liver cancer	7.15e-06	8.6e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—F2—liver cancer	7.14e-06	8.59e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CG—liver cancer	7.12e-06	8.56e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GSTM1—liver cancer	7.07e-06	8.5e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CD—liver cancer	7.06e-06	8.5e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—HPGDS—liver cancer	7.05e-06	8.48e-05	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—PIK3CA—liver cancer	7e-06	8.42e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—SERPINE1—liver cancer	6.98e-06	8.4e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CG—liver cancer	6.97e-06	8.39e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CYCS—liver cancer	6.97e-06	8.38e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CG—liver cancer	6.96e-06	8.38e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—APC—liver cancer	6.96e-06	8.38e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—APC—liver cancer	6.94e-06	8.35e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CG—liver cancer	6.94e-06	8.35e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—KRAS—liver cancer	6.91e-06	8.32e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PPARG—liver cancer	6.87e-06	8.26e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CYP1A1—liver cancer	6.87e-06	8.26e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GGT1—liver cancer	6.84e-06	8.23e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GOT1—liver cancer	6.84e-06	8.23e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—APC—liver cancer	6.83e-06	8.22e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CG—liver cancer	6.83e-06	8.22e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PPARG—liver cancer	6.73e-06	8.09e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CYP1A1—liver cancer	6.7e-06	8.06e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GSTM1—liver cancer	6.66e-06	8.01e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—BRAF—liver cancer	6.54e-06	7.87e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—BRAF—liver cancer	6.52e-06	7.85e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—BRAF—liver cancer	6.42e-06	7.73e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—MTHFR—liver cancer	6.4e-06	7.7e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—PIK3CA—liver cancer	6.35e-06	7.64e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CYP1A1—liver cancer	6.31e-06	7.6e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—RAF1—liver cancer	6.3e-06	7.59e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PSMD10—liver cancer	6.28e-06	7.56e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PSMA4—liver cancer	6.28e-06	7.56e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PPARA—liver cancer	6.28e-06	7.56e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CD—liver cancer	6.26e-06	7.53e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—MTHFR—liver cancer	6.25e-06	7.52e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—ALB—liver cancer	6.18e-06	7.43e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MTOR—liver cancer	6.16e-06	7.41e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CB—liver cancer	6.16e-06	7.41e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTP1—liver cancer	6.14e-06	7.39e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PPARA—liver cancer	6.13e-06	7.37e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CD—liver cancer	6.13e-06	7.37e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CD—liver cancer	6.12e-06	7.36e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GOT2—liver cancer	6.11e-06	7.35e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CD—liver cancer	6.1e-06	7.34e-05	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—PIK3CA—liver cancer	6.06e-06	7.29e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—HMOX1—liver cancer	6.06e-06	7.29e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—SERPINE1—liver cancer	6.05e-06	7.28e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—ALB—liver cancer	6.05e-06	7.28e-05	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—PIK3CA—liver cancer	6.04e-06	7.27e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—SERPINE1—liver cancer	6.03e-06	7.26e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CD—liver cancer	6e-06	7.23e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—KRAS—liver cancer	5.99e-06	7.21e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—KRAS—liver cancer	5.97e-06	7.19e-05	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—PIK3CA—liver cancer	5.95e-06	7.16e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SERPINE1—liver cancer	5.94e-06	7.15e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—MTHFR—liver cancer	5.89e-06	7.08e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—KRAS—liver cancer	5.88e-06	7.07e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—HRAS—liver cancer	5.88e-06	7.07e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CDKN1B—liver cancer	5.78e-06	6.95e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PPARA—liver cancer	5.78e-06	6.95e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP2E1—liver cancer	5.75e-06	6.91e-05	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—AKT1—liver cancer	5.71e-06	6.88e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CASP3—liver cancer	5.66e-06	6.81e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL2—liver cancer	5.65e-06	6.8e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTM1—liver cancer	5.64e-06	6.79e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	5.64e-06	6.79e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—IL6—liver cancer	5.62e-06	6.77e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CCND1—liver cancer	5.51e-06	6.63e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—PIK3CA—liver cancer	5.5e-06	6.62e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—JUN—liver cancer	5.5e-06	6.62e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—PIK3CA—liver cancer	5.49e-06	6.6e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—RAF1—liver cancer	5.46e-06	6.57e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CTNNB1—liver cancer	5.46e-06	6.57e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CB—liver cancer	5.45e-06	6.56e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—RAF1—liver cancer	5.45e-06	6.55e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—PIK3CA—liver cancer	5.4e-06	6.5e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CG—liver cancer	5.38e-06	6.47e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYCS—liver cancer	5.38e-06	6.47e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—RAF1—liver cancer	5.36e-06	6.45e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MMP9—liver cancer	5.35e-06	6.44e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CYP1A1—liver cancer	5.35e-06	6.44e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CB—liver cancer	5.34e-06	6.43e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MTOR—liver cancer	5.33e-06	6.42e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CB—liver cancer	5.33e-06	6.42e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CDKN1A—liver cancer	5.33e-06	6.41e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CB—liver cancer	5.32e-06	6.4e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MTOR—liver cancer	5.32e-06	6.4e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GOT1—liver cancer	5.28e-06	6.35e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GGT1—liver cancer	5.28e-06	6.35e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CG—liver cancer	5.25e-06	6.32e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MTOR—liver cancer	5.23e-06	6.3e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CB—liver cancer	5.23e-06	6.3e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MAPK8—liver cancer	5.2e-06	6.26e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PPARG—liver cancer	5.19e-06	6.24e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—AKT1—liver cancer	5.19e-06	6.24e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—HRAS—liver cancer	5.09e-06	6.13e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—HRAS—liver cancer	5.08e-06	6.11e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PPARG—liver cancer	5.07e-06	6.09e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CDKN1B—liver cancer	5.01e-06	6.02e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—HRAS—liver cancer	5e-06	6.01e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CDKN1B—liver cancer	4.99e-06	6e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—MTHFR—liver cancer	4.99e-06	6e-05	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—AKT1—liver cancer	4.95e-06	5.96e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CG—liver cancer	4.95e-06	5.95e-05	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—AKT1—liver cancer	4.94e-06	5.94e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CDKN1B—liver cancer	4.91e-06	5.91e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CASP3—liver cancer	4.91e-06	5.9e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL2—liver cancer	4.9e-06	5.89e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PPARA—liver cancer	4.89e-06	5.89e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CASP3—liver cancer	4.89e-06	5.88e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL2—liver cancer	4.88e-06	5.88e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—IL6—liver cancer	4.87e-06	5.86e-05	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—AKT1—liver cancer	4.86e-06	5.85e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—IL6—liver cancer	4.86e-06	5.85e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CASP3—liver cancer	4.81e-06	5.79e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL2—liver cancer	4.81e-06	5.78e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—VEGFA—liver cancer	4.8e-06	5.78e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—IL6—liver cancer	4.78e-06	5.75e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CCND1—liver cancer	4.78e-06	5.75e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PPARG—liver cancer	4.77e-06	5.74e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—JUN—liver cancer	4.77e-06	5.73e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CCND1—liver cancer	4.76e-06	5.73e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—STAT3—liver cancer	4.76e-06	5.72e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—JUN—liver cancer	4.75e-06	5.72e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTP1—liver cancer	4.74e-06	5.7e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CTNNB1—liver cancer	4.73e-06	5.69e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CD—liver cancer	4.73e-06	5.69e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CTNNB1—liver cancer	4.71e-06	5.67e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CCND1—liver cancer	4.69e-06	5.64e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—JUN—liver cancer	4.68e-06	5.63e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—HMOX1—liver cancer	4.67e-06	5.62e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—ALB—liver cancer	4.67e-06	5.61e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CTNNB1—liver cancer	4.64e-06	5.58e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MMP9—liver cancer	4.64e-06	5.58e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MMP9—liver cancer	4.62e-06	5.56e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CDKN1A—liver cancer	4.62e-06	5.56e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CD—liver cancer	4.61e-06	5.55e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CDKN1A—liver cancer	4.6e-06	5.54e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—ALB—liver cancer	4.55e-06	5.48e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MMP9—liver cancer	4.55e-06	5.47e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CDKN1A—liver cancer	4.53e-06	5.45e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAPK8—liver cancer	4.51e-06	5.43e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—AKT1—liver cancer	4.5e-06	5.41e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAPK8—liver cancer	4.49e-06	5.41e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—AKT1—liver cancer	4.48e-06	5.39e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAPK8—liver cancer	4.42e-06	5.32e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MYC—liver cancer	4.42e-06	5.32e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—AKT1—liver cancer	4.41e-06	5.31e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TGFB1—liver cancer	4.41e-06	5.31e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.39e-06	5.29e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTM1—liver cancer	4.35e-06	5.24e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CD—liver cancer	4.35e-06	5.23e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ALB—liver cancer	4.29e-06	5.16e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CG—liver cancer	4.19e-06	5.04e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—VEGFA—liver cancer	4.16e-06	5.01e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—VEGFA—liver cancer	4.15e-06	4.99e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP1A1—liver cancer	4.13e-06	4.97e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—STAT3—liver cancer	4.12e-06	4.96e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CB—liver cancer	4.12e-06	4.96e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—STAT3—liver cancer	4.11e-06	4.94e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—VEGFA—liver cancer	4.09e-06	4.92e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—KRAS—liver cancer	4.08e-06	4.91e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—STAT3—liver cancer	4.04e-06	4.87e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PPARG—liver cancer	4.04e-06	4.87e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CB—liver cancer	4.02e-06	4.84e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—MTHFR—liver cancer	3.85e-06	4.63e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MYC—liver cancer	3.83e-06	4.61e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TGFB1—liver cancer	3.82e-06	4.6e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MYC—liver cancer	3.82e-06	4.59e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TGFB1—liver cancer	3.81e-06	4.58e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CB—liver cancer	3.79e-06	4.56e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PPARA—liver cancer	3.78e-06	4.54e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MYC—liver cancer	3.76e-06	4.52e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CA—liver cancer	3.75e-06	4.52e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TGFB1—liver cancer	3.75e-06	4.51e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CD—liver cancer	3.68e-06	4.43e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ALB—liver cancer	3.64e-06	4.38e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TP53—liver cancer	3.63e-06	4.37e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KRAS—liver cancer	3.54e-06	4.26e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KRAS—liver cancer	3.53e-06	4.24e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KRAS—liver cancer	3.47e-06	4.18e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—HRAS—liver cancer	3.47e-06	4.18e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CA—liver cancer	3.32e-06	4e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL6—liver cancer	3.32e-06	4e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CA—liver cancer	3.26e-06	3.92e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CA—liver cancer	3.25e-06	3.91e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CA—liver cancer	3.24e-06	3.9e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CG—liver cancer	3.23e-06	3.89e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CB—liver cancer	3.21e-06	3.86e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CA—liver cancer	3.19e-06	3.84e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TP53—liver cancer	3.15e-06	3.78e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TP53—liver cancer	3.14e-06	3.77e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PPARG—liver cancer	3.12e-06	3.76e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TP53—liver cancer	3.09e-06	3.71e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—AKT1—liver cancer	3.07e-06	3.69e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—HRAS—liver cancer	3.01e-06	3.62e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HRAS—liver cancer	3e-06	3.61e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HRAS—liver cancer	2.95e-06	3.55e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL6—liver cancer	2.88e-06	3.46e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL6—liver cancer	2.87e-06	3.45e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CD—liver cancer	2.84e-06	3.42e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL6—liver cancer	2.83e-06	3.4e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ALB—liver cancer	2.81e-06	3.38e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—AKT1—liver cancer	2.72e-06	3.27e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—AKT1—liver cancer	2.66e-06	3.2e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—AKT1—liver cancer	2.66e-06	3.2e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—AKT1—liver cancer	2.65e-06	3.19e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—AKT1—liver cancer	2.61e-06	3.14e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CA—liver cancer	2.51e-06	3.02e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CB—liver cancer	2.48e-06	2.98e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CA—liver cancer	2.45e-06	2.95e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CA—liver cancer	2.31e-06	2.78e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—AKT1—liver cancer	2.05e-06	2.47e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—AKT1—liver cancer	2e-06	2.41e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CA—liver cancer	1.96e-06	2.35e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—AKT1—liver cancer	1.89e-06	2.27e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—AKT1—liver cancer	1.6e-06	1.92e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CA—liver cancer	1.51e-06	1.82e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—AKT1—liver cancer	1.23e-06	1.48e-05	CbGpPWpGaD
